LAG3 and melanoma: This combination includes Relatlimab (anti-LAG-3 mAb) and Nivolumab (anti-PD-1 mAb), targeting both the LAG-3 and PD-1 for the treatment of unresectable advanced melanoma [50,51,52,53].